<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412876</url>
  </required_header>
  <id_info>
    <org_study_id>109017-F</org_study_id>
    <nct_id>NCT04412876</nct_id>
  </id_info>
  <brief_title>Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study</brief_title>
  <official_title>Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of Duloxetine and Imipramine on therapeutic efficacy, psychological
      distress, sexual function, bladder wall structure and blood flow in women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the impact of Duloxetine and Imipramine on therapeutic efficacy, psychological
      distress, sexual function, bladder wall structure and blood flow in women
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the score of International Consultation on Incontinence Questionnaire-Urinary Incontinence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the score of International Consultation on Incontinence Questionnaire-Urinary Incontinence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the score of Urgency Severity Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the score of Urgency Severity Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the score of Overactive Bladder Symptom Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the score of Overactive Bladder Symptom Score</description>
  </other_outcome>
  <other_outcome>
    <measure>the score of King's health questionnaires</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the score of King's health questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>the score of Brief symptom rating scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the score of Brief symptom rating scale</description>
  </other_outcome>
  <other_outcome>
    <measure>the score of Female sexual function index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the score of Female sexual function index</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood flow index of the bladder</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the changes of blood flow index of the bladder</description>
  </other_outcome>
  <other_outcome>
    <measure>Bladder wall thickness</measure>
    <time_frame>8 weeks</time_frame>
    <description>Between-group difference in the changes of Bladder wall thickness</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive Duloxetine 30 mg treatment per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imipramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive Imipramine 25 mg treatment per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine 30 mg qd</description>
    <arm_group_label>Duloxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>Imipramine 25mg qd</description>
    <arm_group_label>Imipramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Stress urinary incontinence

        Exclusion Criteria:

          1. Take monoamine oxidase

          2. Myocardial infarction critical,cardiovascular insufficiency (such as room blocking,
             arrhythmia, blood-soaked heart failure, myocardial infarction, stroke and excessive
             heartbeat).

          3. Allergy to duloxetine or imipramine

          4. Uncontrolled angular glaucoma patients

          5. Pregnant women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Mou Hsiao, MD</last_name>
    <phone>+886289667000</phone>
    <phone_ext>1818</phone_ext>
    <email>smhsiao2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Mou Hsiao, M.D.</last_name>
      <phone>+886-2-89667000</phone>
      <phone_ext>1818</phone_ext>
      <email>smhsiao2@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 31, 2020</study_first_submitted>
  <study_first_submitted_qc>May 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Comparisons of the impact of duloxetine versus imipramine on therapeutic efficacy, psychological distress, sexual function, urethral and bladder wall structure and blood flow in women with stress urinary incontinence: a randomized controlled study</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

